A novel treatment approach for low grade lymphoproliferative disorders using PKC412 (CGP41251), an inhibitor of protein kinase C

Hematology Journal

Volumn 3, Issue 3, 2002, Pages 131-136

  Virchis, Anders ^a   Ganeshaguru, Kanagasabai ^a   Hart, Steve ^a   Jones, Dylan ^a   Fletcher, Linda ^a   Wright, Faith ^a   Wickremasinghe, Ranmohan ^a   Man, Anthony ^a   Csermark, Katalin ^a   Meyer, Thomas ^a   Fabbro, Doriano ^a   Champain, Kate ^a   Yap, Alan ^a   Prentice, H Grant ^a   Mehta, Atul ^a  

^a BARNET HOSPITAL   (United Kingdom)

Author keywords

CGP 41251; Chronic lymphocytic leukemia; non Hodgkin's lymphoma; PKC 412; Protein kinase C inhibitor

Indexed keywords

AMINOTRANSFERASE; AMYLASE; GLUCOSE; MIDOSTAURIN; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; STAUROSPORINE;

ADULT; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; BLOOD CELL COUNT; BLOOD TRANSFUSION; BONE MARROW DISEASE; CANCER CELL; CANCER GRADING; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HYPERGLYCEMIA; IMMUNOPHENOTYPING; IN VITRO STUDY; LYMPHOCYTE COUNT; LYMPHOPROLIFERATIVE DISEASE; MALE; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; SYMPTOM; TREATMENT OUTCOME; AGED; BLOOD DISEASE; DRUG ANTAGONISM; METABOLISM; MIDDLE AGED; MULTIDRUG RESISTANCE; PHASE 2 CLINICAL TRIAL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; LYMPHOCYTE COUNT; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; PROTEIN KINASE C; STAUROSPORINE;

EID: 0036045471     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200165     Document Type: Article

References (24)

1. The role of protein kinase C in the regulation of cell proliferation and differentiation
2. The potential of protein kinase C as a target for anti-cancer treatment
3. Lipid activation of protein kinase C
4. Protein kinase C as a possible receptor protein of tumor-promoting phorbol esters
5. Overexpression of protein kinase C epsilon is oncogenic in rat colonic epithelial cells
6. Protein kinase C targeting in antineoplastic treatment strategies
7. Programmed cell death and bcl-2 protection in the absence of a nucleus
8. Protein kinase C and mammary cell differentiation: An essential role for PKC-α in the induction of β-casein expression
9. A derivative of staurosporine (CGP 41251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumour activity
10. Anti-tumour effect of CGP 41251, a new selective protein kinase C inhibitor, on human non-small cell lung cancer cells
11. Effect of a new protein kinase C inhibitor CGP 41251 on T cell functions: Inhibition of growth and target cell killing
12. The protein kinase C inhibitor CGP 41251: A staurosporine derivative with anti-tumour activity, reverse multidrug resistance
13. The anti-tumour activity of doxorubicin against drug resistant murine carcinoma is enhanced by oral administration of a synthetic staurosporine analogue, CGP 41251
14. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C
15. The actions of the selective protein kinase inhibitor PKC 412 in B-chronic lymphocytic leukaemia cells in vitro
16. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia
17. Modulation of cellular apoptotic potential: Contributions to oncogenesis
18. Calcium-dependent protein kinase: Widespread occurrence in various tissues and phyla of the animal kingdom and comparison of effects of phospholipid, calmodulin and trifluoperazine
19. Phase I trial of 72-hour continuous infusion UCN-01 in Patients with refractory neoplasms
20. Clinical treatment with CGP 41251 increases sensitivity of CLL cells to conventional therapy
21. UCN-01 chemosensitizes human B-chronic lymphocytic leukemia (B-CLL) cells to the effects of fludarabine
22. UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines
23. Old and new therapies in chronic lymphocytic leukemia: Now is the time for a reassessment of therapeutic goals